Aptevo Therapeutics Inc. Quarterly Debt-to-equity in % from Q3 2016 to Q4 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Aptevo Therapeutics Inc. quarterly Debt-to-equity history and growth rate from Q3 2016 to Q4 2024.
  • Aptevo Therapeutics Inc. Debt-to-equity for the quarter ending December 31, 2024 was 221 %, a 197% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q4 2024 221 +146 +197% Dec 31, 2024
Q3 2024 167 +93.2 +127% Sep 30, 2024
Q2 2024 125 +48.2 +62.4% Jun 30, 2024
Q1 2024 99.8 +25.3 +34% Mar 31, 2024
Q4 2023 74.4 -120 -61.8% Dec 31, 2023
Q3 2023 73.4 -331 -81.8% Sep 30, 2023
Q2 2023 77.2 -620 -88.9% Jun 30, 2023
Q1 2023 74.5 -1.26K -94.4% Mar 31, 2023
Q4 2022 194 -498 -71.9% Dec 31, 2022
Q3 2022 405 -29.4 -6.78% Sep 30, 2022
Q2 2022 697 +262 +60.1% Jun 30, 2022
Q1 2022 1.34K +968 +262% Mar 31, 2022
Q4 2021 693 +477 +220% Dec 31, 2021
Q3 2021 434 +178 +69.8% Sep 30, 2021
Q2 2021 435 +251 +136% Jun 30, 2021
Q1 2021 370 +188 +104% Mar 31, 2021
Q4 2020 216 +47 +27.8% Dec 31, 2020
Q3 2020 256 +117 +85% Sep 30, 2020
Q2 2020 185 +74.8 +68% Jun 30, 2020
Q1 2020 182 +94.4 +108% Mar 31, 2020
Q4 2019 169 +99.9 +144% Dec 31, 2019
Q3 2019 138 +84 +155% Sep 30, 2019
Q2 2019 110 +62.3 +131% Jun 30, 2019
Q1 2019 87.1 +38.2 +77.9% Mar 31, 2019
Q4 2018 69.3 +17.6 +34.1% Dec 31, 2018
Q3 2018 54.2 -6.4 -10.6% Sep 30, 2018
Q2 2018 47.7 -18.3 -27.7% Jun 30, 2018
Q1 2018 49 -6.27 -11.4% Mar 31, 2018
Q4 2017 51.7 +1.1 +2.17% Dec 31, 2017
Q3 2017 60.6 +16.3 +36.8% Sep 30, 2017
Q2 2017 66 Jun 30, 2017
Q1 2017 55.2 Mar 31, 2017
Q4 2016 50.6 Dec 31, 2016
Q3 2016 44.3 Sep 30, 2016
* An asterisk sign (*) next to the value indicates that the value is likely invalid.